Table 1.
Demographic characteristics of the MS patients and healthy control at the time of the stool collection.
| Characteristic | Group 1* (N = 83) | Group3** (N = 34) | Control (N = 26) |
|---|---|---|---|
| Age at diagnosis/enrollment in years (mean) | 46.87 | 57.58 | 42.30 |
| Sex (M/F) | (28/55) | (9/25) | (8/18) |
| Race | Caucasian | Caucasian | Caucasian## |
| BMI kg/m2 (mean) | 30.35 | 28.33 | 27.64 |
| EBV flag*** | 5 | 0 | 0 |
| Diabetes### | 0 | 1 | 1 |
| Hypertension### | 18 | 12 | 3 |
| Therapy | |||
| Disease modifying therapy | 76 | 0 | 0 |
| Fingolimod (oral) | 26 | ||
| Natalizumab (injectable) | 6 | ||
| Ocrelizumab (injectable) | 19 | ||
| Teriflunomide (oral pill) | 6 | ||
| Glatrimer acetate | 6 | ||
| Dimethyl fumarate | 11 | ||
| Interferon beta-1a (injectable) | 1 | ||
| Ritiximab | 1 | ||
| Combination therapy# | 6 | ||
*Group 1 = treated RRMS patients.
** Group 3 = treatment naïve RRMS patients.
***EBV flag = Epstein-Barr virus previous infection.
# On two disease modifying therapy within six months of fecal sample collection.
##All healthy control were white race except for one American Indian or Alaskan native.
###Incomplete electronic health record.